OPRA Pharmacokinetics 2027: Syllabus & MCQs

Pharmacokinetics and Pharmacodynamics accounts for approximately 10% of the OPRA exam syllabus, making it an important subject for overseas-qualified pharmacists preparing for the Australian Pharmacy Council (APC) examination.

For candidates planning to take the OPRA exam in 2027, this subject requires a clear understanding of how medicines are absorbed, distributed, metabolised and eliminated from the body, along with how drug exposure influences pharmacological responses.

Many pharmacy graduates find concepts such as bioavailability, clearance, volume of distribution, half-life and steady-state concentrations challenging. However, understanding these principles can make it easier to interpret medicine-related questions and connect pharmaceutical science with patient care.

This guide covers the OPRA Pharmacokinetics and Pharmacodynamics syllabus for 2027, important concepts, essential formulas, original practice MCQs and effective preparation strategies.

What Is Pharmacokinetics and Pharmacodynamics in the OPRA Exam?

Pharmacokinetics and Pharmacodynamics is one of the five official content areas assessed in the Overseas Pharmacist Readiness Assessment (OPRA).

Although these terms are closely related, they describe different aspects of drug action.

Pharmacokinetics (PK) examines how the body handles a medicine through absorption, distribution, metabolism and excretion.

Pharmacodynamics (PD) examines how medicines produce biological effects, including receptor interactions, dose-response relationships and therapeutic or adverse responses.

A simple way to remember the difference is:

• Pharmacokinetics: What the body does to a drug.

• Pharmacodynamics: What a drug does to the body.

For example, pharmacokinetics helps explain why the concentration of a medicine changes after administration, while pharmacodynamics helps explain how that concentration influences a biological response.

Both are important for understanding safe and effective medicine use.

OPRA Pharmacokinetics and Pharmacodynamics Weightage in 2027

The Australian Pharmacy Council's current OPRA examination guide allocates approximately 10% of questions to Pharmacokinetics and Pharmacodynamics.

The examination contains 120 multiple-choice questions completed in 150 minutes.

Although this content area accounts for approximately 10% of the blueprint, candidates should not assume that every sitting contains exactly 12 scored questions from this subject.

The examination includes scored and unscored questions, and the content percentages represent the published allocation.

There is no separate passing score for Pharmacokinetics and Pharmacodynamics. APC determines the outcome based on overall examination performance.

For the complete subject breakdown, read our OPRA Exam Syllabus and Weightage Guide.

Important Topics in OPRA Pharmacokinetics and Pharmacodynamics

The official APC guide identifies five major content groups.

The following sections explain these topics using practical educational examples.

1. ADME: Absorption, Distribution, Metabolism and Excretion

ADME describes the four major processes influencing the movement and handling of medicines in the body.

Understanding these processes is essential for answering pharmacokinetics questions.

Absorption

Drug absorption is the movement of a medicine from its administration site into the systemic circulation.

Factors affecting absorption include:

• Route of administration

• Drug solubility

• Membrane permeability

• Gastrointestinal pH

• Gastric emptying and intestinal transit

• Food and drug interactions

• Pharmaceutical formulation

For example, a medicine taken orally must generally dissolve and cross biological membranes before reaching the systemic circulation.

Intravenous administration bypasses the absorption step and delivers the administered drug directly into systemic circulation.

Distribution

Drug distribution describes the reversible movement of a medicine between the bloodstream and body tissues.

Important factors include blood flow, tissue permeability, plasma protein binding and the drug's physicochemical characteristics.

Medicines that distribute extensively into tissues may have a relatively large apparent volume of distribution.

However, volume of distribution is a theoretical pharmacokinetic parameter rather than the actual physical volume occupied by a medicine.

Metabolism

Drug metabolism involves the chemical transformation of medicines, often through enzyme-mediated reactions.

The liver is an important organ for drug metabolism, although metabolism can occur in other tissues.

Two commonly discussed categories are:

Phase I reactions: Include oxidation, reduction and hydrolysis. These reactions can introduce or expose functional groups.

Phase II reactions: Include conjugation processes such as glucuronidation and sulfation.

Metabolism may produce inactive metabolites, active metabolites or potentially toxic substances.

Candidates should also understand the significance of enzyme induction and inhibition.

Excretion

Drug excretion removes medicines and their metabolites from the body.

The kidneys are a major route of elimination for many substances.

Other routes include biliary and intestinal excretion, pulmonary elimination and minor routes such as sweat.

Reduced kidney function may decrease clearance of medicines that depend substantially on renal elimination.

Understanding the principal elimination pathway of a medicine is important when evaluating changes in drug exposure.

2. Bioavailability and Bioequivalence

Bioavailability and bioequivalence are important pharmacokinetic principles listed in the APC syllabus.

What Is Bioavailability?

Bioavailability refers to the rate and extent to which an active drug reaches systemic circulation from an administered dosage form.

For intravenous administration, systemic bioavailability is considered 100%.

For oral administration, bioavailability may be reduced by incomplete absorption or first-pass metabolism.

The absolute bioavailability of a drug can be assessed using dose-normalised exposure measurements following non-intravenous and intravenous administration.

What Is Bioequivalence?

Bioequivalence refers to the comparison of drug exposure between pharmaceutical products under specified conditions.

Common pharmacokinetic measures include:

• AUC: Area under the concentration-time curve, which reflects overall systemic drug exposure.

• Cmax: Maximum observed drug concentration.

• Tmax: Time required to reach the maximum observed concentration.

Bioequivalence assessment uses applicable regulatory criteria and appropriate statistical analysis.

Candidates should understand what these parameters represent and how formulation differences can influence drug exposure.

3. Volume of Distribution (Vd)

Volume of distribution is an important pharmacokinetic parameter used to describe the relationship between the amount of drug in the body and its concentration in plasma.

For a simplified model:

Vd = Amount of drug in the body ÷ Plasma drug concentration

A relatively high apparent volume of distribution can indicate extensive distribution outside the plasma.

A relatively low volume may indicate that a greater proportion of the drug remains within the circulating plasma or extracellular fluids.

Solved Example

A hypothetical drug has:

• Amount in the body = 600 mg

• Plasma concentration = 15 mg/L

Calculate the apparent volume of distribution.

Solution:

Vd = 600 ÷ 15

Answer: 40 L

This example illustrates the calculation under a simplified model.

4. Drug Clearance and Elimination

Drug clearance is a pharmacokinetic measure describing the theoretical volume of plasma or blood from which a drug is completely removed per unit time.

Clearance may involve several organs, including the kidneys and liver.

For a simple pharmacokinetic model:

Clearance = Elimination rate ÷ Plasma drug concentration

An important relationship is that reduced clearance can increase drug exposure if the dosing rate remains unchanged.

Factors Affecting Drug Clearance

Clearance can be influenced by:

• Renal function

• Hepatic function

• Blood flow

• Drug-metabolising enzyme activity

• Drug interactions

• Genetic variation

• Physiological changes

Candidates should understand how these factors may alter drug concentrations.

For example, if renal elimination decreases substantially, the concentration of a predominantly renally cleared medicine may rise unless the treatment regimen is appropriately reviewed.

5. Drug Half-Life

Drug half-life is the time required for a drug concentration to decrease by 50% during the relevant elimination phase.

For a simple first-order elimination model:

t½ = 0.693 × Vd ÷ Clearance

Where:

• t½ = Elimination half-life

• Vd = Volume of distribution

• Clearance = Drug clearance

Solved Example

A hypothetical medicine has:

• Volume of distribution = 35 L

• Clearance = 5 L/hour

Calculate the elimination half-life.

Solution:

t½ = (0.693 × 35) ÷ 5

t½ = 24.255 ÷ 5

Answer: Approximately 4.85 hours

Why Is Half-Life Important?

Half-life helps explain how drug concentrations decline and can contribute to understanding dosing intervals, accumulation and the time needed to approach steady state.

However, half-life alone does not determine every aspect of a dosing regimen.

Patient factors, medicine properties, therapeutic response and safety must also be considered.

6. Steady-State Drug Concentrations

Steady state occurs when the average rate of drug administration equals the average rate of drug elimination.

With repeated dosing or continuous infusion under linear pharmacokinetic conditions, drug concentrations generally approach steady state over time.

A commonly taught approximation is that steady state is approached after approximately four to five elimination half-lives.

These percentages apply to a simplified first-order model with constant drug input and linear elimination.

Real medicines may behave differently, particularly when pharmacokinetics are nonlinear or when patient physiology changes.

Why Is Steady State Important for OPRA?

Steady-state concepts help explain drug accumulation, the timing of drug concentration measurements and the effects of changes in clearance or dosing.

Candidates should understand the principle rather than memorising only the percentages.

7. Factors Affecting Drug Onset and Duration

The time required for a medicine to produce an effect and the duration of that effect depend on multiple factors.

These can include:

• Route of administration

• Absorption rate

• Bioavailability

• Distribution

• Clearance

• Drug-receptor interactions

• Active metabolites

• Formulation characteristics

For example, a modified-release oral preparation may produce a different concentration-time profile from an immediate-release preparation.

However, the difference depends on the drug and formulation.

Diet can also influence drug absorption. Food may delay absorption, increase exposure, decrease exposure or have little effect, depending on the specific medicine.

Candidates should avoid assuming that food always reduces or increases absorption.

8. Pharmacokinetics in Renal and Hepatic Dysfunction

The APC syllabus specifically includes the use of pharmacokinetic information when evaluating medicine therapy in patients with renal or hepatic dysfunction.

Renal Dysfunction

Reduced renal function may affect drug elimination.

If a medicine or active metabolite is substantially eliminated by the kidneys, impaired renal function can increase exposure.

Relevant concepts include:

• Renal clearance

• Glomerular filtration

• Drug accumulation

• Dose adjustment principles

• Therapeutic monitoring

Not every medicine requires the same adjustment, and changes should not be based on estimated kidney function alone without considering the drug and patient.

Hepatic Dysfunction

The liver contributes to the metabolism and elimination of many medicines.

Hepatic dysfunction can alter enzyme activity, hepatic blood flow, protein binding and other physiological factors.

These changes can affect drug exposure, but their consequences vary between medicines.

Candidates should understand the underlying principles rather than assume that every drug requires the same dose reduction in liver disease.

9. Pharmacokinetics of Low-Therapeutic-Index Drugs

The therapeutic index describes the relationship between doses or exposures producing desired and toxic effects.

Medicines with a narrow therapeutic index may require particular attention because relatively small changes in exposure can influence efficacy or toxicity.

Examples often discussed in pharmacokinetic education include:

• Digoxin

• Lithium

• Phenytoin

• Certain immunosuppressants

For such medicines, concentration monitoring may help support treatment decisions when interpreted alongside clinical information.

Therapeutic Drug Monitoring

Therapeutic drug monitoring involves measuring drug concentrations to help evaluate exposure and guide individualised treatment.

Important considerations include:

• Timing of the blood sample

• Time since the last dose

• Whether steady state has been reached

• Renal or hepatic function

• Drug interactions

• Clinical response and adverse effects

The measured concentration should always be interpreted in the appropriate clinical context.

10. Pharmacodynamics: Drug Concentration and Response

Pharmacodynamics concerns the relationship between a medicine's exposure and its effects on the body.

Important concepts include receptor binding, signal transduction, potency and efficacy.

Potency describes the amount or concentration required to produce a specified response.

Efficacy refers to the ability of a drug to produce a biological effect.

A more potent drug is not necessarily more effective clinically or safer.

A medicine may require a lower concentration to produce a given response while having a similar maximum effect to another medicine.

Understanding these distinctions can help candidates interpret concentration-response curves.

For deeper drug-receptor theory, revise the Pharmacology and Toxicology section of the official OPRA syllabus.

OPRA Pharmacokinetics and Pharmacodynamics Practice MCQs

The following questions are independently created educational examples. They are not official or recalled APC examination questions.

Question 1: Drug Absorption

Which route of administration provides 100% systemic bioavailability by definition?

A. Oral
B. Intramuscular
C. Intravenous
D. Subcutaneous

Correct Answer: C. Intravenous

Explanation: Intravenous administration delivers the drug directly into systemic circulation, bypassing absorption barriers and first-pass metabolism.

Question 2: Volume of Distribution

A hypothetical drug has an amount in the body of 400 mg and a plasma concentration of 10 mg/L.

What is its apparent volume of distribution?

A. 10 L
B. 20 L
C. 40 L
D. 80 L

Correct Answer: C. 40 L

Explanation:

Vd = Amount ÷ Concentration

400 mg ÷ 10 mg/L = 40 L.

Question 3: Drug Clearance

What is the MOST likely result of reduced renal clearance for a drug eliminated predominantly unchanged by the kidneys, assuming its dosing rate remains constant?

A. Reduced systemic drug exposure
B. Increased systemic drug exposure
C. Complete prevention of drug absorption
D. Immediate loss of all pharmacological activity

Correct Answer: B. Increased systemic drug exposure

Explanation: Reduced clearance can increase drug concentrations and exposure when drug administration remains unchanged.

Question 4: Half-Life

A drug follows first-order elimination and has a half-life of eight hours. Its initial concentration is 80 mg/L.

What would the approximate concentration be after 24 hours without further drug administration?

A. 40 mg/L
B. 20 mg/L
C. 10 mg/L
D. 5 mg/L

Correct Answer: C. 10 mg/L

Explanation: Twenty-four hours represents three half-lives.

80 → 40 → 20 → 10 mg/L.

Question 5: Steady State

Under linear pharmacokinetic conditions, approximately how many elimination half-lives are generally required to approach 94–97% of steady state?

A. One
B. Two
C. Four to five
D. Ten to twelve

Correct Answer: C. Four to five

Explanation: Under a simple first-order model, approximately 93.75% of steady state is reached after four half-lives and 96.875% after five.

Question 6: Bioavailability

Which pharmacokinetic parameter primarily reflects overall systemic drug exposure over a specified period?

A. Tmax
B. AUC
C. Molecular weight
D. Melting point

Correct Answer: B. AUC

Explanation: The area under the concentration-time curve reflects drug exposure over time.

Question 7: Therapeutic Drug Monitoring

Which factor is particularly important when interpreting a measured plasma concentration of a drug requiring therapeutic drug monitoring?

A. The colour of the tablet packaging
B. The patient's preferred pharmacy
C. The timing of the blood sample in relation to drug administration
D. Whether the medicine is stored in a cardboard carton

Correct Answer: C. The timing of the blood sample in relation to drug administration

Explanation: Sampling time influences how a measured concentration should be interpreted, particularly for medicines where peak, trough or steady-state measurements are relevant.

Question 8: Pharmacodynamics

Which statement BEST describes drug efficacy?

A. The amount of medicine required to produce a particular effect
B. The maximum biological response a medicine can produce in a defined system
C. The speed at which a medicine is eliminated
D. The percentage of medicine bound to plasma proteins

Correct Answer: B. The maximum biological response a medicine can produce in a defined system

Explanation: Efficacy relates to the capacity to generate a biological response. Potency describes the amount or concentration needed to produce a specified effect.

How to Prepare for OPRA Pharmacokinetics and Pharmacodynamics in 2027

An effective preparation strategy should combine scientific understanding, calculations and practical interpretation of pharmacokinetic information.

Step 1: Understand ADME Thoroughly

Begin with absorption, distribution, metabolism and elimination.

Understand how physiological factors and drug properties influence each process.

Step 2: Revise Core Pharmacokinetic Parameters

Focus on bioavailability, volume of distribution, clearance, half-life and steady state.

Learn what each parameter represents and how it is interpreted.

Step 3: Practise Concentration-Time Questions

Review concentration-time curves and understand AUC, Cmax, Tmax and drug elimination patterns.

Step 4: Understand Patient-Specific Changes

Study how changes in renal function, hepatic function, age and drug interactions can influence exposure.

Step 5: Practise Relevant Calculations

Include questions involving half-life, volume of distribution, clearance and loading doses.

For solved numerical examples, explore our OPRA Exam Calculations Guide.

Step 6: Review Mistakes Regularly

Maintain an error journal identifying the concepts you misunderstood and revisit them during your next study session.

Seven-Day OPRA Pharmacokinetics Revision Timetable

This is an independently suggested revision plan, not an APC-prescribed timetable.

Common Mistakes to Avoid

Confusing pharmacokinetics with pharmacodynamics: Remember that PK concerns drug disposition, while PD concerns drug effects.

Memorising formulas without understanding their meaning: Learn how clearance, volume of distribution and half-life are connected.

Ignoring the assumptions behind calculations: Simple formulas may not apply directly to nonlinear pharmacokinetic systems.

Confusing potency with efficacy: A more potent medicine does not necessarily produce a greater maximum therapeutic effect.

Neglecting patient-specific factors: Renal function, liver function, age and drug interactions can significantly affect drug exposure.

Conclusion

Preparing for OPRA Pharmacokinetics and Pharmacodynamics in 2027 requires a strong understanding of how medicines move through the body and how drug exposure relates to biological effects.

Although this subject accounts for approximately 10% of the examination blueprint, its concepts are closely connected to pharmacology, toxicology and patient care.

Focus on understanding ADME, clearance, bioavailability, volume of distribution, half-life, steady state and therapeutic drug monitoring.

Combine these concepts with original practice questions and regular revision to strengthen your pharmaceutical science knowledge.

Explore Free OPRA Preparation Resources

• Complete OPRA Exam Syllabus

• Free OPRA Sample Papers

• OPRA Calculations and Practice MCQs

• OPRA Exam Study Plan for Working Pharmacists

• 20-Question OPRA Readiness Quiz

Need help planning your OPRA preparation? Request free OPRA preparation guidance through the enquiry form on OPRAExam.in.

The website provides independent educational resources and is not affiliated with the Australian Pharmacy Council.

Official References

1. Australian Pharmacy Council — OPRA Exam Guide and Sample Content

2. Australian Pharmacy Council — Knowledge Stream

Last reviewed: 7 November 2026

Disclaimer: OPRAExam.in is an independent educational website and is not affiliated with or endorsed by the Australian Pharmacy Council. All practice questions and hypothetical drug examples are independently created for educational use and do not represent clinical prescribing guidance. Candidates should verify the latest official examination requirements before applying.